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Background/aim: The aims of this study were to detect CCND1, C-MYC, and FGFR1 amplification using qPCR, confirmation with
FISH, and to further assess their clinicopathological relevance.
Materials and methods: Thirty-five breast tumor samples were analyzed for amplification of the selected genes using modified SYBR
Green qPCR. The accuracy of the qPCR was assessed by FISH as a gold-standard method.
Results: CCND1, C-MYC, and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples, respectively.
qPCR results were significantly confirmed by FISH and qPCR and FISH showed excellent correlation (P = 0.000). CCND1 amplification
with tumor stage (P = 0.044), positive metastatic status (P = 0.042), positive family history (P = 0.042), and C-MYC status (P = 0.005);
C-MYC amplification with tumor size (P = 0.021), tumor grade (P = 0.018), tumor stage (P = 0.032), and FGFR1 status (P < 0.000); and
FGFR1 amplification with tumor size (P = 0.041) and positive ER status (P = 0.042) were statistically associated.
Conclusion: Our findings revealed that the applied qPCR approach could precisely quantify the relative gene copy number. More
studies with a larger sample size are suggested to confirm the clinicopathological value of CCND1, C-MYC, and FGFR1 amplification.
Key words: Breast cancer, fluorescent in situ hybridization, gene amplification, gene copy number, real-time polymerase chain reaction

1. Introduction
Cancer originates from the interaction of the environment
and accumulative genetic changes such as mutations, copy
number variations (CNVs), and epigenetic alterations.
Gene amplification (GA) is one type of CNV known as the
increase of a defined cytogenetic region of chromosomes
called amplicons. CNVs are a common event in solid
tumors and GA is the main mechanism that leads to the
activation of protooncogenes (1). Chromosomal positions
at 1q, 8p12, 8q24, 11q13, 12p13, 16p13, 7q12-21, and
20q13, and several target oncogenes including ERBB2,
MYCL1, MYCN, REL, EGFR, FGFR1, CCND1, TOP2A,
and C-MYC, have been the most prominent and frequent
amplicons identified in breast cancer (BC). There are
many common amplification-activated human oncogenes
identified in different cancers (2–4).
Cyclin D1 is encoded by the CCND1 gene and has a
prominent role in the progression of a cell through the
G1 phase of the cell cycle by complexing with cyclindependent kinases CDK4 and CDK6. CCND1 amplification
has been identified in a variety of tumors, among which
10%–15% of human primary breast cancers have shown

amplification in the 11q13 chromosomal region (5). There
are numerous studies that ascertain whether CCND1
amplification might be associated with clinicopathological
variables and clinical outcome as a biological marker in
BC; however, the results are contradictory (6). C-MYC
encodes a transcription factor that regulates cell growth,
proliferation, metabolism, differentiation, and apoptosis.
It is amplified in the range of 10%–16% in BC. Although
it is reported to be related to the risk of relapse and death,
its prognostic value is not completely clear (7). The
fibroblast growth factor receptor 1 gene (FGFR1) provides
information for producing a tyrosine kinase receptor
and is amplified in 9% to 15% of BC cases, thought to be
correlated with poor prognosis in BC (8).
Given the crucial prognostic and predictive information
that can be obtained by the analysis of CCND1, C-MYC,
and FGFR1 amplification, rapid, accurate, and reliable
methods for quantification are required. Depending on
the required resolution, rapidity, cost, application, etc.,
the method of choice for gene quantification could be
different, but each technique has some advantages and
disadvantages. Although array and probe-based methods
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are powerful tools for genome scanning or simultaneous
study of multiple genetic markers, they may be complicated
and difficult to be automated, validated, standardized,
and interpreted. Therefore, they may not be appropriate
options for clinical applications and to only assess a small
number of target genes (9–11).
qPCR can, however, determine the overall amplification
of genes accurately. It is often homogeneous and reduces
time, the risk of contamination, and manual errors. qPCR
is objective, fast, versatile, sensitive, specific, and timeand cost-effective and can be performed on a limited
number of DNA samples. Gene dosage is measured by two
approaches in qPCR: fluorescent dyes and intercalating
dyes. Regardless of the approach, fluorescence doubles with
every cycle of PCR, and the amount of gene copy can be
determined based on the number of cycles required to rise
above a specified threshold level of fluorescence. Doublestranded DNA-speciﬁc binding dye-based detection
systems are more cost-effective, simpler to design, and
easier to set up than hydrolysis probes, molecular beacons,
and dual hybridization probe-based strategies (12,13).
The aims of this study are fourfold: to assess the accuracy
of SYBR Green qPCR for detection of gene amplification;
to analyze the amplification of CCND1, C-MYC, and
FGFR1 amplification in an early-onset BC population
using SYBR Green qPCR; to analyze the correlations
between CCND1, C-MYC, and FGFR1 amplifications and
clinicopathological features; and to define the correlations
of CCND1, C-MYC, and FGFR1 amplifications with each
other.
2. Materials and methods
2.1. Sample preparation
Thirty-five fresh frozen BC tissue specimens were used
in the present study. All the participating patients in the
study had early-onset invasive ductal breast carcinoma.
All the histopathological diagnoses were performed by
pathologists. DNA and cell suspensions were used for
qPCR and FISH analysis, respectively. Ten samples taken
from a cosmetic breast surgery center were used as the
calibrator. The present work was performed under the
approval of the Research Ethics Committee of Tehran
University of Medical Science (Tehran, Iran) and according
to the Declaration of Helsinki, and a signed consent form
was received from each patient.
2.2. DNA extraction and SYBR Green qPCR
Total DNA was extracted from microdissected fresh
frozen BC specimens using a QIAamp kit (QIAGEN,
Hilden, Germany) according to the instructions of the
manufacturer. A modified E Cp (gene of interest in calibrator) – Cp (gene of
interest in case)
formula was used to determine the relative copy
number (RCN) of selected genes based on the fact that there
are no differences in the quality and quantity of starting
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material and there is no difference in PCR efficiency
between target genes (14). Therefore, sections of tumor
tissues containing >80% cancerous cells were dissected
for downstream qPCR and FISH analysis. All extracted
DNAs were assessed for quantity and quality with a
NanoDrop 2000 (Thermo Fisher Scientific, Waltham,
MA, USA). DNA samples of 40 ng/µL, 260/280 = 1.8–
1.9, were provided for qPCR assay. Five 10-fold serial
dilutions were prepared and the efficiency of each primer
was determined according to E = 10 – 1/slope. RCN was
measured by SYBR Green-based qPCR using the following
primers: 5’-GATTGGAGGCACACGTCTCA-3’ and
5’-GCTCAGCTACGTTGGTCACT-3’ for CCND1,
5’-AAAAGTGGGCGGCTGGATAC-3’
and
5’
AGGGATGGGAGGAAACGCTA-3’
for
C-MYC,
and
5’-CCGCTCCCTAAACTTGCTGA-3’
and
5’-AGGAATGAGACGGGATTGCG-3’ for FGFR1.
PCR reactions of 10 µL were run in a Rotor-Gene 2000
(QIAGEN) using SYBR Premix Ex Taq (Tli RNaseH
Plus, Takara Bio, Shiga, Japan) according to the following
program: initial heating at 95 °C for 30 s, and 40 cycles
of denaturation at 95 °C for 10 s and annealing and
extension at 60 °C for 30 s. Melting curve analysis from
60 to 99 °C was also run to assess specific amplification of
target regions in each sample. All quantification analyses
were accomplished based on the cycle of a threshold
value (Cp). All reactions were run in duplicate and mean
Cp was put into RCN calculations. RCNs of <0.6, 0.6–1.5,
1.5–3, and >3 were considered as loss, normal, gain, and
amplified, respectively. Those samples with RCN of >2.5
were analyzed by FISH as the gold-standard method.
2.3. Fluorescence in situ hybridization (FISH) analysis
XL CCND1, XL MYC amp, and XL FGFR1 probe kits
(Metasystems, Altlußheim, Germany) were used for
FISH analysis of the target genes. In summary, tissue
samples of 10 µm were treated with pepsin for 90 min at
37 °C and were ﬁxed in 1:3 acetic acid:methanol solution.
Specimens were spotted onto clean microscopic slides,
air-dried, and incubated in 2X saline sodium citrate
(SSC) buffer (pH 7–7.5) containing 0.9% Tween-20 (pH
7) at 37 °C for 30 min; dehydrated in 70%, 80%, and 95%
ethanol (each for 1 min at room temperature); washed
with ddH2O; and left to air-dry. The next steps were
conducted according to the manufacturer’s instructions
with a little modification whereby the codenaturation
time was increased to 6 min and the posthybridization
time of washing with 0.4X SSC was increased to 5 min.
The slides were counterstained with DAPI/antifade and
analyzed with a microscope (Leica, Wetzlar, Germany)
after 10 min. The signal of the target gene was scored
in 200 nuclei and the ratio of signals/number of scored
cells was measured. Ratios of >2.2 were considered as
signifying gene amplification.
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2.4. Statistical analysis
The cut-off point for assigning negative and positive status
for SYBR Green qPCR was established by plotting receiver
operating characteristic (ROC) curves. The correlation
between methods was determined by calculating the
Spearman correlation coefficient. The chi-square test
or Fisher exact test was used when comparing gene
amplification frequencies between groups and analyzing
associations of gene amplification with clinicopathological
characteristics. P < 0.05 was considered statistically
significant. All P-values reported are two-sided. The
statistical software package used for these analyses was
SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Samples
Thirty-five female patients with early-onset BC were
enrolled in this study. The population of the study was
in normal distribution; the maximum and minimum
participant ages were 16 and 49 years old, and mean ± SD
was 37.54 ± 8.83 years.
3.2. Copy number quantification by SYBR Green qPCR
Gene copy number (GCN) measurement of CCND1,
C-MYC, and FGFR1 was performed for 35 fresh frozen BC
specimens using a double-stranded DNA-speciﬁc binding
dye (SYBR)-based qPCR strategy. Percentages of samples
showing CNRs of >3, 1.5–3, 0.6–1.5, and <0.6 are shown
in Figure 1. Samples with RCN of >2.5 were also analyzed

by FISH for assessing the accuracy of qPCR results. The
detection performance or accuracy of the applied SYBR
Green qPCR test was compared to FISH in order to
discriminate amplified from nonamplified conditions
using ROC curve analysis. The area under the ROC
curve (AUC) is a measure of how well a test can precisely
discriminate these conditions. AUC values for detection
of CCND1, C-MYC, and FGFR1 amplification were 0.90,
0.85, and 0.83, respectively. Based on these findings, RCN
of ≥3 was considered as the amplification cut-off point of
the target genes.
3.3. FISH analysis
As indicated, samples with RCN of >2.5 were analyzed
by FISH in order to confirm the accuracy of the applied
SYBR Green qPCR and identify the true amplification cutoff point. Comparison of the results of applied methods
with ROC curve analysis showed RCN of ≥3 as the true
amplification point. However, FISH analysis showed a few
inconsistencies. One sample for CCND1 and one sample
for FGFR1 were unamplified based on FISH. Also, one
sample with RCN of 2.75 was amplified for C-MYC by
FISH analysis. There were a total of three samples with an
ambiguous score that were retested and finally 2 samples
were scored as normal and one sample was scored as
amplified. The highest to lowest correlation rate between
the two applied methods was observed for CCND1 (0.815;
P < 0.000), C-MYC (0.775; P < 0.000), and FGFR1 (0.720;
P < 0.000) (Table 1).
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Figure 1. Percentage of BC samples with RCNs* of <0.6, 0.6–1.5, 1.5–3, and >3 measured using qPCR. *Relative copy
numbers. RCNs of <0.6, 0.6–1.5, 1.5–3, and >3 were considered as loss, normal, gain, and amplified, respectively.
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Table 1. Comparison of qPCR-FISH for detection of amplification in CCND1, C-MYC, and
FGFR1 genes.
P-value

Correlation
coefficient*

<0.000

0.815

Amplified (%)
4 (28.6)
10 (71.4)

<0.000

0.775

Amplified (%)
2 (28.6)
5 (71.4)

<0.000

0.720

CCND1-FISH
CCND1-qPCR
Unamplified
Amplified

Normal (%)
21 (95.5)
1 (4.5)

Amplified (%)
2 (15.4)
11 (84.6)

C-MYC-FISH
C-MYC-qPCR
Unamplified
Amplified

Normal (%)
21 (100)
0 (0)
FGFR1-FISH

FGFR1-qPCR
Unamplified
Amplified

Normal (%)
27 (96.4)
1 (3.6)

*Spearman correlation (Spearman’s rho) between the applied methods to detect CCND1, C-MYC,
and FGFR1 amplification; >0.70 demonstrates a strong positive linear relationship.

3.4. Association of CCND1, C-MYC, and FGFR1 status
with clinicopathological features
The clinical and tumor characteristics of the included
samples according to CCND1, C-MYC, and FGFR1 status are
shown in Tables 2 and 3. CCND1 amplification is statistically
associated with tumor stage 1+2 (P = 0.044), positive nodal
metastasis (P = 0.042), positive family history (P = 0.02),
and C-MYC status (P = 0.005); however, CCND1 is not
significantly related to age at diagnosis, tumor grade, tumor
size, ER status, or FGFR1 status (Table 2). C-MYC status was
significantly related to larger tumor size (P = 0.021), higher
tumor grade (P = 0.018), higher tumor stage (P = 0.032), and
FGFR1 status (P < 0.000). There was no significant correlation
between C-MYC status and all the other clinicopathological
parameters (Table 2). FGFR1 amplification was statistically
correlated with tumor size (P = 0.041), C-MYC status (P <
0.000), and positive ER status (P = 0.042). Association of
FGFR1 status with other clinicopathological characteristics
was not significant (Table 3).
4. Discussion
Pathogenic variations in GCNs are a hallmark of cancer that
frequently occur in the process of cancer development. Gene
amplification is a major strategy of oncogene overexpression
in malignant tumors (15–17). Thus, DNA-based copy
number detection methods could be helpful for the better
management of cancer including therapeutic decisions
and prognosis detection. Due to the greater stability of
DNA compared to RNA and proteins, gene amplification
detection assays may therefore be optimally appropriate for
diagnostic applications (16).
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Although there are different methods for measuring
the GCN, a fast, reproducible, and cost-effective method
is required. qPCR has individual advantages including
rapidity, cost-effectiveness, and accuracy. Two different
PCR-based methods of presenting quantitative GCN
exist: absolute and relative quantification. Absolute
quantification calculates the copy number of the gene
usually by relating the PCR signal to a standard curve.
Relative GCN quantification presents the data of the
gene of interest relative to some calibrator or internal
control gene. Based on the authors’ knowledge, absolute
quantification or relative quantification based on
hybridization probes has previously been applied to GCN
quantification. qPCR techniques based on hybridization
probes are still expensive and are hard to optimize. In
the present study, modified SYBR Green-based relative
quantification was utilized for measuring the GCNs of
three crucial oncogenes, CCND1, C-MYC, and FGFR1, in
early-onset BC samples. The modified E–∆Ct formula was
used for measuring RCNs of the target genes in tumor
samples compared to the calibrator, assuming that there
are no differences in the quantity of starting material and
no difference in PCR efficiency between target genes in
DNA samples extracted from tumor and normal calibrator
tissues. To achieve a highly specific, sensitive, and efficient
qPCR reaction, different criteria and steps including
microdissection of tumor tissue to obtain the area
containing >80% cancer cells, selection of regions, primer
design and in silico quality control, empirical validation
of primers, and standard curve and melting curve analysis
were considered in the process of this work’s design. The
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Table 2. Patient and tumor characteristics according to CCND1 and C-MYC status.
CCND1*
Amplified number
(%)

CCND1
Unamplified number
(%)

P-value

C-MYC
Amplified number
(%)

C-MYC
Unamplified number
(%)

10 (28.6)

25 (71.4)

P-value

All

12 (34.3)

23 (65.7)

Age at diagnosis
>30 years
<30 years

3 (25)
9 (75)

6 (26.1)
17 (73.9)

0.944

2 (20)
8 (80)

7 (28)
18 (72)

0.625

Tumor size, cm
>2
<2

6 (50)
6 (50)

18 (78.3)
5 (21.7)

0.087

4 (40)
6 (60)

20 (80)
5 (20)

0.021

Tumor grade
Grade 1+2
Grade 3

1 (8.3)
11 (91.7)

9 (39.1)
14 (60.9)

0.056

0 (0)
10 (100)

10 (40)
15 (60)

0.018

Tumor stage
Stage 1+2
Stage 3

14 (60.9)
9 (39.1)

3 (25)
9 (75)

0.044

2 (20)
8 (80)

15 (60)
10 (40)

0.032

ER* status
Positive
Negative

5 (41.7)
7 (58.3)

11 (47.8)
12 (52.2)

0.728

4 (40)
6 (60)

15 (60)
10 (40)

0.283

PR* status
Positive
Negative

4 (33.3)
8 (66.7)

9 (39.1)
14 (60.9)

0.736

6 (60)
4 (40)

16 (64)
9 (36)

0.825

Metastatic status
Positive
Negative

10 (83.3)
2 (16.7)

11 (47.8)
12 (52.2)

0.042

2 (20)
8 (80)

Family history
Negative
Positive

10 (83.3)
2 (16.7)

11 (47.8)
12 (52.2)

0.042

5 (50)
5 (50)

C-MYC status
Normal
Amplified

5 (41.7)
7 (58.3)

20 (87)
3 (13)

0.005

FGFR1* status
Normal
Amplified

8 (66.7)
4 (33.3)

21 (91.3)
2 (8.7)

0.066

4 (40)
6 (60)

25 (100)
0 (0)

<0.000

1

3 (30)
7 (70)

20 (80)
5 (20)

0.005

CCND1 status
Normal
Amplified

12 (48)
13 (52)
16 (64)
9 (36)

0.125

0.445

1

*CCND1: Cyclin D1, ER: estrogen receptor, PR: progesterone receptor, FGFR1: fibroblast growth factor receptor 1.

accuracy of the applied formula was confirmed using
the common method of relative quantification, 2–∆∆Ct, in
which the HBB (hemoglobin, beta) and RPLP0 (ribosomal
protein 109 lateral stalk subunit P0) genes were amplified
as internal controls. Comparison of the two methods of
qPCR-relative quantification confirmed the high accuracy
of the modified E–∆Ct formula. Although probe-based
or absolute quantification relating the PCR signal to a

standard curve has been used to detect GCNs (18,19), to
the best of the authors’ knowledge, relative quantification
to detect RCNs by relating the PCR signal of the target
genes in one group to another is applied for the first time
in human tumor samples in the current study.
Additionally, the accuracy of the applied SYBR Green
qPCR was also assessed by FISH as the gold standard
(Figure 2). qPCR results in comparison to FISH results
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Table 3. Patient and tumor characteristics according to FGFR1 status.
FGFR1
Amplified number (%)

FGFR1
Unamplified number (%)

All

6 (17.1)

29 (82.9)

Age at diagnosis
>30 years
<30 years

2 (33.3)
4 (66.7)

7 (24.1)
22 (75.9)

0.639

Tumor size, cm
>2
<2

2 (33.3)
4 (66.7)

22 (75.9)
7 (24.1)

0.041

Tumor grade
Grade 1+2
Grade 3

0 (0)
6 (100)

10 (34.5)
19 (65.5)

0.089

Tumor stage
Stage 1+2
Stage 3

1 (16.7)
5 (83.3)

16 (55.2)
13 (44.8)

0.086

ER status (IHC)
Negative
Positive

1 (16.7)
5 (83.3)

18 (62.1)
11 (37.9)

0.042

PR status (IHC)
Negative
Positive

5 (83.3)
1 (16.7)

17 (58.6)
12 (41.4)

0.254

Metastatic status
Negative
Positive

2 (33.3)
4 (66.7)

12 (41.4)
17 (58.6)

0.714

Family history
Negative
Positive

2 (33.3)
4 (66.7)

19 (65.5)
10 (34.5)

0.143

CCND1 status
Normal
Amplified

2 (33.3)
4 (66.7)

21 (72.4)
8 (27.6)

0.066

C-MYC status
Normal
Amplified

0 (0)
6 (100)

25 (86.2)
4 (13.8)

<0.000

were plotted in the ROC curve to illustrate the qPCR
diagnostic ability, including sensitivity and specificity, for
detection of RCNs of selected genes. The graphs in Figure
3 show three ROC curves representing excellent (CCND1)
and good (C-MYC and FGFR1) ability of the applied
qPCR. The accuracy of the qPCR assay was measured by
the AUC, which was 0.90, 0.857, and 0.839 for CCND1,
C-MYC, and FGFR1, respectively. Correlation coefficients
between CCND1-qPCR, C-MYC-qPCR, and FGFR1qPCR and FISH were 0.815, 0.775, and 0.720 (P < 0.000),
respectively (Figure 2; Table 1).
These findings indicate that the applied qPCR approach
has a strong linear relationship with FISH and can relatively
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quantify the copy number of target genes from only a few
biopsy cells with high sensitivity and specificity. However,
this approach might face some limitations, including
sensitivity to DNA quality and quantity, more difficult
interpretation, sensitivity to finding a true cut-off point
of amplification, sensitivity to mosaicism, contamination
with a large number of normal stromal cells, and
methodological and experimental errors. One sample
with RCN of >3 was negative in FISH for FGFR1 and one
sample with RCN of 2.75 was positive in FISH for C-MYC,
which could be due to these mentioned limitations.
Association of selected genes status with patient
and tumor characteristics was also assessed as a further

AZARNEZHAD et al. / Turk J Med Sci

Figure 2. Confirmation of CCND1, C-MYC, and FGFR1 gene amplification by fluorescence in situ hybridization (FISH). a) Gene
amplification of CCND1 in BC tumor sample 1. A tumor with multiple individual CCND1 signal-type amplifications (green-orange).
CCND1 relative copy number in BC tumor 1 is 11.15 based on qPCR. 1000×. b) Gene amplification of C-MYC in BC tumor sample 14.
A tumor with clustered and multiple individual HER2 signal-type amplification (C-MYC signal is displayed in orange and green signal
represents centromere region). C-MYC relative copy number in BC tumor 14 is 4.56 based on qPCR. 1000×. c) Gene amplification of
FGFR1 in BC tumor sample 23. A tumor with multiple individual CCND1 signal-type amplifications (green-orange). C-MYC relative
copy number in BC tumor 23 is 5.89 based on qPCR. 1000×.

Figure 3. Receiver operating characteristic (ROC) curves. These graphical plots illustrate the diagnostic ability, including the sensitivity
and specificity, of the applied SYBR Green qPCR approach. Correlation of qPCR and FISH was calculated by statistical Spearman
correlation test: a) ROC curve of qPCR to detect RCN of CCND1, b) ROC curve of qPCR to detect RCN of C-MYC, c) ROC curve of
qPCR to detect RCN of FGFR1.

aim. As we performed the current work on a specific
type of BC, early-onset invasive ductal carcinoma, the
essential inclusion and exclusion criteria for the study
population led to the limitation of the sample size. This
could be considered as a limitation of the study. CCND1
amplification has been observed in 10%–27% of BC
cases (20). Prognostic properties of CCND1 in BC have
been reported in several studies with conflicting results
(5,6). It has also been shown that CCND1 amplification
preferentially occurs in estrogen receptor-positive BC
and CCND1 amplification has been suggested as being

associated with resistance to tamoxifen therapy (21). In
the present study, CCND1 amplification was observed in
34.3% (12/35) of samples. Our data showed that CCND1
amplification might be a poor prognostic biomarker and
a significant relation was found between its status and age
at diagnosis, tumor grade, tumor size, ER status, positive
family history, and FGFR1 status. It could be concluded
from the association with positive family history that either
inheritance of a pathogenic mutation in key genes such
as BRCA1/2 and P53 may drive amplification of CCND1
or this connection may be due to small sample size and
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is not the true relation. Correlation between CCND1 and
FGFR1 could be explained by their crosstalk in cell growth
pathways and tumorigenesis. It has been demonstrated
that CCND1 and FGFR1 coamplification results in the
localization of 11q13 and 8p12 sequences in breast tumor
nuclei (22). C-amplification of CCND1 and C-MYC was
observed in 7 amplified samples, which probably reflects
the possible synergistic contribution to tumorigenesis.
C-MYC is a pivotal regulator of up to 15% of human
genes (23). Gene amplification is one of the common
mechanisms of C-MYC deregulation in BC and it is also
amplified among a variety of solid cancers (24). Although
C-MYC amplification has been observed in a range of 8%–
37% in BC, C-MYC amplification in the present work was
28.6% (16,25). The overwhelming majority of studies have
demonstrated the association of C-MYC amplification
with tumor grade, lymph node metastasis, negative
progesterone receptor status, postmenopausal status, the
risk of relapse and death, and poor prognosis (23). Our
findings revealed a considerable association between
C-MYC status and larger tumor size, higher tumor grade,
higher tumor stage, and FGFR1 status that could confirm
the poor prognostic value of C-MYC amplification. It
could also be concluded that C-MYC may play a role in an
FGFR1-dependent model of BC tumorigenesis.
FGFR1 is located at cytogenetic location 8p11.23,
which initiates a cascade signaling pathway and triggers
mitogenesis and differentiation. FGFR1 was one of the
first genes found to be amplified in 10% of BC patients;
however, our data showed 17.14% (5/35) amplification.
FGFR1 amplifications are reported to be associated with
anchorage-independent proliferation, endocrine therapy
resistance, early relapse, and poor survival, particularly in
ER-positive BC (8,26). In the current study, coamplification

of CCND1 and FGFR1 was observed in 4 amplified
samples, which means that they possibly cooperate in
oncogenesis. Coamplification of FGFR1 and C-MYC
occurred in 6 amplified samples, which might be either
due to polyploidy of chromosome 8 or their synergistic
roles. FGFR1 amplification was also statistically correlated
with tumor size, C-MYC status, and positive ER status.
Altogether, the applied qPCR strategy using generic
dsDNA dyes in the present study revealed sensitive,
accurate, and cost-effective abilities for determining the
RCNs of the selected genes. Our findings also showed
a considerable correlation between qPCR and FISH;
however, a suitable cut-off point for qPCR is a prerequisite
for determining the exact status of target genes.
Microdissection is also proposed to take a pure cancer
cell sample so as to eliminate normal cell contamination.
The SYBR Green I assay could also be applied in a number
of conditions where gene amplification is involved in
disease etiology. Additionally, CCND1, C-MYC, and
FGFR1 amplifications seem to convey prognostic value.
Coamplification of the selected genes proposes intergene
cooperation and a synergistic role in BC tumorigenesis.
Nonetheless, more studies with larger sample sizes are
suggested to confirm our findings.
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